Dyadic Launches Animal-Origin-Free Recombinant DNase I
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy DYAI?
Dyadic Applied BioSolutions and Fermbox Bio announced the commercial launch of animal-origin-free Recombinant DNase I. This represents the first commercialized product under the companies expanded collaboration announced in 2025 and marks another step in Dyadic's accelerating transition from platform development to commercial product expansion and recurring revenue growth. Produced using Dyadic's proprietary high-yield fungal microbial expression platforms and Fermbox Bio's scale-up and biomanufacturing capabilities, Recombinant DNase I is currently available in research grade with a cGMP-grade version in development to support biopharmaceutical manufacturing and cell and gene therapy applications. Recombinant DNase I is an endonuclease enzyme used for nucleic-acid clean-up and sample preparation workflows where residual DNA can interfere with analytical results. Its RNase-free specification supports RNA integrity in sensitive RNA workflows across biological research, biotechnology, and molecular diagnostics. DNase I is a strategically important enzyme and the first in a planned series of recombinant enzymes and proteins expected to be commercially introduced throughout 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DYAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DYAI
About DYAI
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dyadic International Reports FY 2025 Earnings Results
- Earnings Performance: Dyadic International reported a FY 2025 GAAP EPS of -$0.23, aligning with market expectations, indicating ongoing challenges in profitability.
- Revenue Decline: The company's revenue for FY 2025 was $3.09 million, representing an 11.7% year-over-year decrease and missing market expectations by $0.77 million, reflecting a lack of sales growth.
- Cash Flow Status: As of December 31, 2025, Dyadic's total cash, cash equivalents, restricted cash, and investment-grade securities amounted to $8.6 million, down from $9.29 million in 2024, highlighting increased liquidity pressure.
- Future Outlook: Dyadic aims to achieve product revenue growth and commercialization milestones in 2026 while expanding partnerships, intending to improve future financial performance and market competitiveness.
See More
Dyadic International Q4 2025 Earnings Call Insights
- Accelerated Commercialization: Since assuming the role of President in June 2025, Joseph Hazelton emphasized that the company has rapidly transitioned from a development stage to a commercial product-driven biotechnology firm, indicating multiple paths for revenue diversification are forming.
- Revenue Growth Potential: Total revenue for 2025 was $3.09 million, a decrease from $3.5 million in 2024; however, the increase of $1.86 million in grant revenue from the Gates Foundation and CEPI demonstrates the company's diversification in funding sources.
- Product Launches and Collaborations: The commercial collaboration with Proliant Health & Biologicals for recombinant albumin marks the launch of the first platform-enabled product, expected to generate recurring revenue, while the agreement with BRIG BIO will enhance market penetration for animal-free recombinant products.
- Future Outlook: Management anticipates revenue growth in product sales for 2026, emphasizing disciplined cash usage and prioritization of high-impact R&D projects to support ongoing growth in life sciences and food and nutrition markets.
See More
Dyadic (DYAI) Q4 2025 Earnings Call Transcript
See More
Dyadic Launches AlbuFree™ DX Recombinant Human Albumin
- Product Commercialization Progress: Proliant Health & Biologicals successfully launched AlbuFree™ DX recombinant human albumin in February 2026, with Dyadic entitled to a share of profits from sales, marking a significant step in the company's commercialization efforts in the biopharmaceutical sector.
- Strategic Collaboration Expansion: Dyadic expanded its partnership with Fermbox Bio, launching the first commercialized animal-origin-free DNase I (RNase-free), which not only enriches Dyadic's product portfolio but also enhances its competitiveness in the biotechnology market.
- OEM Distribution Agreement Signed: Dyadic entered into an OEM distribution agreement with IBT Bioservices to commercialize recombinant DNase I and transferrin through IBT's global distribution channels, which is expected to significantly enhance Dyadic's market reach and sales capabilities.
- Nutrition Market Development Agreement: Dyadic signed a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-lactalbumin, which is anticipated to create new revenue streams for the global nutrition market, further driving the company's growth strategy.
See More
DYADIC INTERNATIONAL, INC. Reports FY EPS of USD -0.23
Company Overview: DYA DIC International, Inc. is a company involved in various sectors, including finance and technology.
Market Performance: The company's stock, FYEP, is currently trading at $0.23, indicating its market position and investor interest.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Dyadic International Reports FY 2025 Earnings Results
- Earnings Performance: Dyadic International reported a FY 2025 GAAP EPS of -$0.23, aligning with market expectations, indicating ongoing challenges in profitability.
- Revenue Decline: The company's revenue for FY 2025 was $3.09 million, representing an 11.7% year-over-year decrease and missing market expectations by $0.77 million, reflecting a lack of sales growth.
- Cash Flow Status: As of December 31, 2025, Dyadic's total cash, cash equivalents, restricted cash, and investment-grade securities amounted to $8.6 million, down from $9.29 million in 2024, highlighting increased liquidity pressure.
- Future Outlook: Dyadic aims to achieve product revenue growth and commercialization milestones in 2026 while expanding partnerships, intending to improve future financial performance and market competitiveness.
See More
Dyadic International Q4 2025 Earnings Call Insights
- Accelerated Commercialization: Since assuming the role of President in June 2025, Joseph Hazelton emphasized that the company has rapidly transitioned from a development stage to a commercial product-driven biotechnology firm, indicating multiple paths for revenue diversification are forming.
- Revenue Growth Potential: Total revenue for 2025 was $3.09 million, a decrease from $3.5 million in 2024; however, the increase of $1.86 million in grant revenue from the Gates Foundation and CEPI demonstrates the company's diversification in funding sources.
- Product Launches and Collaborations: The commercial collaboration with Proliant Health & Biologicals for recombinant albumin marks the launch of the first platform-enabled product, expected to generate recurring revenue, while the agreement with BRIG BIO will enhance market penetration for animal-free recombinant products.
- Future Outlook: Management anticipates revenue growth in product sales for 2026, emphasizing disciplined cash usage and prioritization of high-impact R&D projects to support ongoing growth in life sciences and food and nutrition markets.
See More
Dyadic (DYAI) Q4 2025 Earnings Call Transcript
See More
Dyadic Launches AlbuFree™ DX Recombinant Human Albumin
- Product Commercialization Progress: Proliant Health & Biologicals successfully launched AlbuFree™ DX recombinant human albumin in February 2026, with Dyadic entitled to a share of profits from sales, marking a significant step in the company's commercialization efforts in the biopharmaceutical sector.
- Strategic Collaboration Expansion: Dyadic expanded its partnership with Fermbox Bio, launching the first commercialized animal-origin-free DNase I (RNase-free), which not only enriches Dyadic's product portfolio but also enhances its competitiveness in the biotechnology market.
- OEM Distribution Agreement Signed: Dyadic entered into an OEM distribution agreement with IBT Bioservices to commercialize recombinant DNase I and transferrin through IBT's global distribution channels, which is expected to significantly enhance Dyadic's market reach and sales capabilities.
- Nutrition Market Development Agreement: Dyadic signed a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-lactalbumin, which is anticipated to create new revenue streams for the global nutrition market, further driving the company's growth strategy.
See More
DYADIC INTERNATIONAL, INC. Reports FY EPS of USD -0.23
Company Overview: DYA DIC International, Inc. is a company involved in various sectors, including finance and technology.
Market Performance: The company's stock, FYEP, is currently trading at $0.23, indicating its market position and investor interest.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
